Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision
King of Prussia, Pennsylvania--(Newsfile Corp. - July 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today significant progress in the protection of its proprietary innovations across key international markets. The company has received multiple favorable patent actions encompassing three
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-15 7:00 AM EDT | Phio Pharmaceuticals Corp.
Trenchant Technologies Capital Corp. Announces Closing of First Tranche of the Private Placement of Convertible Debentures
Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTC Pink: AITTF) ("Trenchant" or the "Company") is pleased to announce that, further to its news release of July 03, 2026, that it has closed a first tranche on July 10, 2026 (the "First Tranche") of its private placement (the "Offering"), and has issued 500 debentures (the "Debentures") for gross proceeds of $500,000. Trenchant anticipates closing the rema
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-07-14 8:13 PM EDT | Trenchant Technologies Capital Corp.
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - July 14, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced positive 12-month data from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. The Stage 1 cohort demonstrated a mean Consonant-Nucleus-Consonant ("CNC") word recognition
Biotechnologies, Soins de santé et hôpitaux
2026-07-14 9:17 AM EDT | Envoy Medical, Inc.
Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks
Vancouver, British Columbia--(Newsfile Corp. - July 14, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide a strategic operational update regarding its collaboration with the Richardson Centre for Food Technology and Research (RCFTR) at the University of Manitoba. Following the recent unveiling of its newly formulated product roadmap, targeted to capitalize on emerging consumer shopping patterns, the Comp
Technologies, Biotechnologies, Santé
2026-07-14 6:00 AM EDT | Restart Life Sciences Corp.
Nextleaf Evolves Glacial Gold, Building Trust with Wellness Consumers
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce the evolution of Glacial Gold, the Company's flagship consumer cannabis brand. The most significant evolution in Glacial Gold's history, a milestone that reflects Nextleaf's continued development into a consumer-packaged goods ("CPG") comp
Biotechnologies, Pharmaceutique, Cannabis, Extracteurs de cannabis
2026-07-13 9:29 AM EDT | Nextleaf Solutions Ltd.
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.
Biotechnologies, Pharmaceutique, Santé
2026-07-13 8:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
Highlights Meuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel's four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-09 7:00 AM EDT | TempraMed Technologies Ltd.
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM"). "
2026-07-09 7:00 AM EDT | Telo Genomics Corp.
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Biotechnologies, Pharmaceutique, Santé
2026-07-08 10:08 AM EDT | Hemostemix Inc.
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from the U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) to review the Company's pharmacodynamic response biomarker data (the "OST-HER2 Biomarker Data") –
2026-07-08 9:00 AM EDT | OS Therapies
Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to provide an update on its forward-looking product development and segment expansion roadmap for its wholly owned subsidiary, Holy Crap Foods Inc. Following the Company's recent disclosure of its preliminary June 2026 financial growth highlights, management is working to build upon this operational trajectory b
Technologies, Biotechnologies, Santé
2026-07-08 6:00 AM EDT | Restart Life Sciences Corp.
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development a
Biotechnologies, Pharmaceutique, Santé
2026-07-08 3:15 AM EDT | Defence Therapeutics Inc.
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a who
Biotechnologies, Pharmaceutique
2026-07-06 6:20 PM EDT | InMed Pharmaceuticals
OS Therapies Third Quarter 2026 Corporate Outlook
New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on upcoming clinical and regulatory milestones for the Company's lead program OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Me
2026-07-06 9:00 AM EDT | OS Therapies
CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
Houston, Texas--(Newsfile Corp. - July 6, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announces that Dante Picazo, Chief Executive Officer of the Company, has designated 500,000,000 shares of common stock from his personal holdings to honor the directors, employees, and key associates whose dedication, loyalty, and work have helped shape CBIH's journey and strengthen the Company through years
Biotechnologies, Pharmaceutique, Cannabis, Santé
2026-07-06 7:00 AM EDT | Cannabis Bioscience International Holdings
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
Highlights TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medications LOI includes minimum annual purchase commitments in Year 1 Expands TempraMed's footprint across the Middle East and supports broa
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-07-06 7:00 AM EDT | TempraMed Technologies Ltd.
Trenchant Technologies Capital Corp. Announces Private Placement Offering of up to $1 Million Convertible Debentures
Vancouver, British Columbia--(Newsfile Corp. - July 3, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (the "Company" or "Trenchant") is pleased to announce a private placement (the "Offering") of convertible debentures (each, a "Debenture") for gross proceeds of up to $1,000,000. The Offering consists of the issuance of convertible debentures of the Company (the "Debentures") bearing interest at a rate of 12% per annum and maturing one year f
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-07-03 4:00 PM EDT | Trenchant Technologies Capital Corp.
Modern Luxury Vegas Recognizes Dr. Christina Rahm Among Its 2026 Power Players
Las Vegas, Nevada--(Newsfile Corp. - July 2, 2026) - Dr. Christina Rahm, renowned scientist, entrepreneur, humanitarian and founder of DRC Ventures and ROOT Brands, was recognized as one of Modern Luxury Vegas' 2026 Power Players and joined fellow honorees at a celebration hosted by Modern Luxury Vegas on June 11. Held at Maroon, the invitation-only gathering brought together leaders featured in the publication's Power Players initiative, which highlights influential individuals shapin
Biotechnologies, Aliments / boissons, Santé
2026-07-02 4:32 PM EDT | DRC Ventures
Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC
British Columbia and Casablanca, Morocco--(Newsfile Corp. - July 2, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that, further to its
2026-07-02 8:00 AM EDT | Izotropic Corporation
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has appointed Dr. Craig Eagle to the Company's Board of Directors. Dr. Eagle currently serves as the Company's Chief Medical Advisor
2026-07-02 7:30 AM EDT | OS Therapies